Physician profile
Dusan I Pekovic
NPI 1568532687
$28,263.55
in general payments reported to CMS, 2019-2025
24 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,801 · 2020: $1,981 · 2021: $3,454 · 2022: $3,173 · 2023: $5,910 · 2024: $3,982 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,854.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,886.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $4,546.02 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $2,492.20 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $2,172.08 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $2,095.31 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $1,762.69 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,677.47 | 2020-2025 | Caplyta |
| Allergan, INC. | $1,642.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,423.03 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,180.70 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $911.33 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $683.06 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $635.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $526.82 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $318.20 | 2021-2024 | Loreev Xr, Sertraline Hcl |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $255.19 | 2022-2024 | Quviviq |
| Tris Pharma INC | $196.31 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Bausch Health US, LLC | $171.58 | 2022-2023 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $166.77 | 2019 | |
| Validus Pharmaceuticals LLC | $155.33 | 2020 | |
| Avanir Pharmaceuticals, INC. | $147.94 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.99 | 2019 | |
| Indivior INC. | $65.65 | 2021-2023 | Perseris |
| Janssen Scientific Affairs, LLC | $26.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dusan Pekovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.